In Vivo: VU0152100 (10, 30, 56.6 mg/kg; i.p.; single) reverses amphetamine-induced hyperlocomotion in rats. VU0152100 (10, 30, 56.6 mg/kg; i.p.; single) blocks amphetamine-induced disruption of the acquisition of contextual fear conditioning and prepulse inhibition of the acoustic startle reflex in rats. VU0152100 reverses amphetamine-induced increases in extracellular dopamine levels in nucleus accumbens and caudate-putamen.